Caldera Medical, a leader in women’s health medical devices, has acquired Ethicon’s Gynecare TVT™ family of products and will transition the products in the coming months. This strategic milestone builds on Caldera Medical’s 23-year commitment to delivering best-in-class therapies that improve the quality of life for women worldwide.
The TVT product line – consisting of TVT, TVT Exact, TVT-O and TVT Abbrevo, provides minimally invasive treatment options for women with stress urinary incontinence (SUI). As part of the acquisition, Caldera Medical will maintain the same manufacturing facility, materials, and dedicated manufacturing team behind the TVT products, ensuring a seamless transition for surgeons, patients, and partners. With more than two decades of clinical data, including 20-year patient follow-up, the trusted performance and efficacy of TVT remain unchanged.
“This acquisition marks a significant advancement in our mission to transform women’s health,” said Bryon Merade, CEO of Caldera Medical. “By bringing the TVT product line into our portfolio, we reinforce our unwavering commitment to providing safe, effective solutions for surgeons and their patients. We are honored to build on the legacy and expand the reach of this esteemed product family, delivering proven treatments to more women around the world.”
Caldera Medical will expand global customer support for TVT over the next several months and invest in advancing care for a greater number of women. Combining Caldera Medical’s established expertise in pelvic health with TVT’s demonstrated success, the company further solidifies its position as a premier provider of advanced solutions for women. This acquisition follows the September 2023 acquisition of Atlantic Therapeutics with the Innovo non-invasive solution for bladder leaks and the October 2024 acquisition of UVision360 with the Luminelle product line for hysteroscopy and cystoscopy. These acquisitions not only accelerate Caldera Medical’s growth but underscore its dedication to broadening access to life-changing treatments, backed by a legacy of clinical success and a focus on improving patient outcomes.
